NTP CHEMICAL REPOSITORY (RADIAN CORPORATION, AUGUST 29, 1991)
IDENTIFIERS
CAS NUMBER: 555-30-6
BASE CHEMICAL NAME: METHYLDOPA
PRIMARY NAME: METHYL DOPA
CHEMICAL FORMULA: C10H13NO4
STRUCTURAL FORMULA: (HO)2C6H3CH2C(CH3)(NH2)CO2H
SYNONYMS:
L-(-)-BETA-(3,4-DIHYDROXYPHENYL)-ALPHA-METHYLALANINE
L-(-)-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE
L-ALPHA-METHYL-3,4-DIHYDROXYPHENYLALANINE
L-(-)-ALPHA-METHYL-BETA-(3,4-DIHYDROXYPHENYL)ALANINE
ALPHA-METHYL-L-3,4-DIHYDROXYPHENYLALANINE
ALPHA-METHYL-BETA-(3,4-DIHYDROXYPHENYL)-L-ALANINE
METHYLDOPA
ALDOMET
AMD
BAYER 1440 L
BAYPRESOL
DOPAMET
DOPATEC
DOPEGYT
L-(ALPHA-MD)
(-)-METHYLDOPA
L-METHYLDOPA
L-ALPHA-METHYLDOPA
ALPHA-METHYL-L-DOPA
MK. B51
MK 351
NCI-C55721
PRESINOL
3-HYDROXY-ALPHA-METHYL-L-TYROSINE
3-HYDROXY-ALPHA-METHYL-L-TYROSINE SESQUIHYDRATE
L-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE
L-2-AMINO-2-AMINO-2-METHYL-3-(3,4-DIHYDROXYPHENYL)PROPIONIC ACID SESQUIHYDRATE
ALDOMETIL
ALDOMIN
ALPHA MEDOPA
HYPERPAX
MEDOMET
MEDOPREN
METHOPLAIN
ALPHA-METHYL DOPA
NR.C 2294
PRESOLISIN
SEDOMETIL
SEMBRINA
ALPHA-METHYLDOPA
ALDOMINE
MEDOPA
3-HYDROXY-ALPHA-METHYLTYROSINE
2-AMINO-3-(3,4-DIHYDROXYPHENYL)-2-METHYLPROPIONIC ACID
PHYSICAL CHEMICAL DATA
PHYSICAL DESCRIPTION: LITERATURE: Colorless or almost colorless crystals or
white to yellowish-white fine powder
REPOSITORY: White powder
MOLECULAR WEIGHT: 211.21
SPECIFIC GRAVITY: Not available
DENSITY: Not available
MP (DEG C): ~300 C (decomposes) [033,047,365]
BP (DEG C): Not available
SOLUBILITIES:
WATER : 1-10 mg/mL @ 23 C (RAD)
DMSO : 10-50 mg/mL @ 21 C (RAD)
95% ETHANOL : <1 mg/mL @ 23 C (RAD)
METHANOL : <1 mg/mL @ 20 C (RAD)
ACETONE : <1 mg/mL @ 21 C (RAD)
TOLUENE : <1 mg/mL @ 20 C (RAD)
OTHER SOLVENTS:
Alcohol: 1 in 400 @ 20 C [455]
Common organic solvents: Practically insoluble [029,033]
Dilute mineral acids: Soluble [033]
Ether: Insoluble [365]
Dilute hydrochloric acid: 1 in 0.5 [295,365]
Chloroform: Insoluble [365]
VOLATILITY:
Vapor pressure: Not available
Vapor density : Not available
FLAMMABILITY(FLASH POINT):
Flash point data for this chemical are not available; however, it is
probably combustible. Fires involving this material can be controlled with
a dry chemical, carbon dioxide or Halon extinguisher.
UEL: Not available LEL: Not available
REACTIVITY:
This chemical undergoes catalytic oxygenation in the presence of
magnesium, cupric, cobalt, nickel and ferric ions [365].
STABILITY:
This chemical is very hygroscopic [033,365]. It may be sensitive to
prolonged exposure to air and light [295,455]. The stability of aqueous
solutions is markedly dependent on pH, oxygen and the amount of initial
reactant. Aqueous solutions are stable for up to 50 hours in acid and
neutral pH (6.2). At pH 8.0, decomposition products are formed in 3 to 5
hours [365]. Solutions of this chemical in DMSO, 95% ethanol or acetone
should be stable for 24 hours under normal lab conditions. (RAD)
OTHER PHYSICAL DATA:
This compound is the sesquihydrate form
pH of saturated aqueous solution: ~5.0 [033]
UV max (in 0.1 N hydrochloric acid): 280 nm (E = 115) [455]
Optical rotation: -4.0 +/- 0.5 degrees @ 23 C (concentration = 1 in
0.1 N hydrochloric acid [033]
Optical rotation: -5.2 degrees @ 25 C (concentration = 2.0 in 0.1 N hydro-
chloric acid) [029]
Optical rotation: -14 degrees @ 20 C (concentration = 1.09 in water) [029]
Almost tasteless [295,455]
A solution in water containing aluminum chloride is levorotatory [295]
pKa (NH3): 10.35 [365]
Solutions develop a red tint that becomes progressively darker (eventually
forming a black precipitate) [365]
Odorless [052,158,295,455]
TOXICITY
NIOSH REGISTRY NUMBER: AY5950000
TOXICITY:
typ. dose mode specie amount units other
LD50 orl rat 5000 mg/kg
LD50 ipr mus 150 mg/kg
LD50 ivn mus 1700 mg/kg
LD50 orl rbt 713 mg/kg
LD50 ivn rbt 713 mg/kg
LD50 ipr rat 300 mg/kg
TDLo orl wmn 900 mg/kg/13W-I
TDLo orl wmn 1830 mg/kg/17W-I
TDLo orl man 1071 mg/kg/22W-I
TDLo orl wmn 44 gm/kg/3Y-I
AQTX/TLM96: Not available
SAX TOXICITY EVALUATION:
THR: Poison by intraperitoneal route. Moderately toxic by ingestion and
intravenous routes. A suspected carcinogen. An experimental teratogen.
Human reproductive effects by unspecified route. Experimental repro-
ductive effects. Mutagenic data.
CARCINOGENICITY:
Status: NTP Carcinogenesis Studies (Feed): No Evidence: Male and Female Rat,
Female Mouse [620]
NTP Carcinogenesis Studies (Feed): Equivocal Evidence: Male Mouse
[620]
MUTATION DATA: See RTECS printout for most current data
test lowest dose | test lowest dose
----------- ----------------- | ----------- -----------------
cyt-ham:lng 37 mg/L | dlt-mus-orl 960 mg/kg
TERATOGENICITY: See RTECS printout for most current data
Reproductive Effects Data:
TDLo: unr-wmn 10950 mg/kg (2Y pre/1-12W preg)
TDLo: unr-wmn 58 gm/kg (2Y pre)
TDLo: unr-wmn 1680 mg/kg (28-36W preg)
TDLo: scu-rat 300 mg/kg (1D pre)
TDLo: scu-mus 80 mg/kg (1D pre)
TDLo: orl-rat 2100 mg/kg (1-21D preg)
TDLo: orl-rat 7500 mg/kg (6-20D preg)
TDLo: orl-rat 13 gm/kg (65D male)
TDLo: orl-mus 480 mg/kg (1D male)
TDLo: orl-mus 960 mg/kg (1D male)
STANDARDS, REGULATIONS & RECOMMENDATIONS:
OSHA: None
ACGIH: None
NIOSH Criteria Document: None
NFPA Hazard Rating: Health (H): None
Flammability (F): None
Reactivity (R): None
OTHER TOXICITY DATA:
Status: EPA TSCA Chemical Inventory, 1986
Meets criteria for proposed OSHA Medical Records Rule
EPA Genetox Program 1988, Inconclusive: Histidine reversion-Ames test
OTHER DATA (Regulatory)
PROPER SHIPPING NAME (IATA): Not restricted
UN/ID NUMBER:
HAZARD CLASS: SUBSIDIARY RISK: PACKING GROUP:
LABELS REQUIRED:
PACKAGING: PASSENGER: PKG. INSTR.: MAXIMUM QUANTITY:
CARGO : PKG. INSTR.: MAXIMUM QUANTITY:
SPECIAL PROVISIONS:
USES:
This compound is used as an antihypertensive.
COMMENTS: Not available
HANDLING PROCEDURES
ACUTE/CHRONIC HAZARDS:
When heated to decomposition this compound emits toxic fumes of nitrogen
oxides [043].
MINIMUM PROTECTIVE CLOTHING: Not available
RECOMMENDED GLOVE MATERIALS:
GlovES+ Expert System Glove Types For The Neat (Undiluted) Chemical:
This chemical has not been tested for permeation by Radian Corporation;
however, the GlovES+ expert system was used to extrapolate permeation test
information from compounds in the same chemical class. The GlovES+ system uses
permeation data from literature sources; therefore, extra safety margins should
be used with the estimated protection time(s). If this chemical makes direct
contact with your glove, or if a tear, puncture or hole develops, replace them
at once.
The GlovES+ expert system is a tool that can help people better manage
protection from chemicals, however this tool cannot replace sound judgment nor
make technical decisions. Our GlovES+ expert system is designed to offer
initial advice and assistance in glove selection while the final glove
selection should be made by knowledgeable individuals based on the specific
circumstances involved.
Glove Type Model Number Thickness Estimated Protection Time
PVC Edmont 34-100 0.20 mm 240 min
Nitrile North LA-142G 0.36 mm 240 min
Neoprene Edmont 29-870 0.46 mm 480 min
Viton North F-091 0.25 mm 480 min
RECOMMENDED RESPIRATOR:
Where the neat test chemical is weighed and diluted, wear a NIOSH-
approved half face respirator equipped with an organic vapor/acid gas
cartridge (specific for organic vapors, HCl, acid gas and SO2) with a
dust/mist filter.
OTHER: Not available
STORAGE PRECAUTIONS:
You should keep this material in a tightly closed container
under an inert atmosphere, and store it at refrigerated temperatures.
SPILLS AND LEAKAGE:
If you spill this chemical, you should dampen the solid spill material
with water, then transfer the dampened material to a suitable container. Use
absorbent paper dampened with water to pick up any remaining material. Seal
your contaminated clothing and the absorbent paper in a vapor-tight plastic
bag for eventual disposal. Wash all contaminated surfaces with a soap
and water solution. Do not reenter the contaminated area until the Safety
Officer (or other responsible person) has verified that the area has been
properly cleaned.
DISPOSAL AND WASTE TREATMENT: Not available
EMERGENCY PROCEDURES
SKIN CONTACT:
IMMEDIATELY flood affected skin with water while removing and isolating
all contaminated clothing. Gently wash all affected skin areas thoroughly
with soap and water.
If symptoms such as redness or irritation develop, IMMEDIATELY call a
physician and be prepared to transport the victim to a hospital for treatment.
INHALATION:
IMMEDIATELY leave the contaminated area; take deep breaths of fresh air.
If symptoms (such as wheezing, coughing, shortness of breath, or burning in
the mouth, throat, or chest) develop, call a physician and be prepared to
transport the victim to a hospital.
Provide proper respiratory protection to rescuers entering an unknown
atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA)
should be used; if not available, use a level of protection greater than or
equal to that advised under Respirator Recommendation.
EYE CONTACT:
First check the victim for contact lenses and remove if present. Flush
victim's eyes with water or normal saline solution for 20 to 30 minutes while
simultaneously calling a hospital or poison control center.
Do not put any ointments, oils, or medication in the victim's eyes without
specific instructions from a physician.
If symptoms (such as redness or irritation) develop, immediately transport
the victim to a hospital.
INGESTION:
DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing,
give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a
hospital or poison control center. Be prepared to transport the victim to a
hospital if advised by a physician.
If the victim is convulsing or unconscious, do not give anything by mouth,
ensure that the victim's airway is open and lay the victim on his/her side with
the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport
the victim to a hospital.
SYMPTOMS:
Symptoms of exposure to this compound include edema (fluid retention),
fever, diarrhea, mental depression, hepatic toxicity, arthralgia (with or
without joint swelling), leukopenia, breast enlargement, amenorrhea,
pancreatitis, myocarditis and hemolytic anemia [158,301]. Parkinsonism,
hypertension and galactorrhea (lactation) may occur [295,301]. Reversible
keratitis may also occur [099]. Other symptoms include sedation (usually
transient), asthenia, congestive heart failure, weight gain, vomiting,
sialadenitis, sore or "black" tongue, distention, flatus, hyperprolactin-
emia, bone marrow depression, rheumatoid factor, abnormal liver function
tests, pericarditis, decreased mental acuity, symptoms of cerebrovascular
insufficiency, psychic disturbances including nightmares and reversible
mild psychoses, rise in BUN, toxic epidermal necrosis and decreased libido
[158]. Exposure can cause headache, weakness, aggravation of angina pectoris,
prolonged carotid sinus hypersensitivity, postural hypotension, bradycardia,
colitis, nausea, constipation, dryness of the mouth, granulocytopenia, thrombo-
cytopenia, positive tests for antinuclear antibody, LE cells, positive Coombs
test, liver disorders including hepatitis and jaundice, lupus-like syndrome,
Bell's palsy, involuntary choreoathetotic movements, dizziness, lightheaded-
ness, paresthesias, myalgia, nasal stuffiness, skin rash and impotence [158,
295]. Exposure can also cause drowsiness, gastrointestinal upset, disorders of
sexual function, salivary gland inflammation, uremia, liver damage (including
cirrhosis), darkened urine, eosinophilia, syncope, cholestasis, eczema, oral
ulceration, hyperpyrexia, ocular disturbances, febrile reaction, joint pain,
nodular skin lesions, retroperitoneal fibrosis and biliary carcinoma. There
has been a case of reversible malabsorption with partial villous atrophy,
inflammatory infiltrate of the mucosa and giant-cell granuloma [295]. Other
symptoms may include sleep disturbances, anxiety, blurred vision, hepatic
necrosis and lichenoid and granulomatous skin reactions [406]. It may also
cause menstrual cycle changes or disorders and effects on the newborn including
abnormal neonatal measures, growth statistics and biochemical and metabolic
changes [043].
SOURCES
SOURCES:
[015] Lewis, R.J., Sr. and R.L. Tatken, Eds. Registry of Toxic Effects
of Chemical Substances. On-line Ed. National Institute for
Occupational Safety and Health. Cincinnati, OH. AY5950000.
October 5, 1989.
[029] Buckingham, J., Ed. Dictionary of Organic Compounds. 5th Ed. and
Supplements. Chapman and Hall. New York. 1988. Vol. 4, p. 3839,
#M-01671.
[033] Budavari, Susan, Ed. The Merck Index. 11th Ed. Merck and Co., Inc.
Rahway, NJ. 1989. p. 953, #5974.
[043] Sax, N.I. and Richard J. Lewis, Sr. Dangerous Properties of Industrial
Materials. 7th Ed. Van Nostrand Reinhold. New York. 1989.
Vol. II, p. 1301, #DNA800.
[047] Weast, R.C. and M.J. Astle, Eds. CRC Handbook of Data on
Organic Compounds. CRC Press, Inc. Boca Raton, FL.
1985. Vol. II, p. 407, #T01569.
[052] Midwest Research Institute. MRI Report for Methyl dopa sesquihydrate.
Kansas City, MO. October 30, 1984.
[082] U.S. Environmental Protection Agency, Office of Toxic Substances.
Toxic Substances Control Act Chemical Substance Inventory: 1985
Edition. 5 Vols. U.S. Environmental Protection Agency.
Washington, D.C. January 1986. Listed.
[099] Grant, W. Morton, M.D. Toxicology of the Eye. 3rd Ed. Charles
C. Thomas, Publisher. Springfield, IL. 1986. p. 615.
[110] Oak Ridge National Laboratory. Environmental Mutagen Information
Center (EMIC), Bibliographic Data Base. Oak Ridge National
Laboratory. Oak Ridge, TN. Listed.
[120] Oak Ridge National Laboratory. Environmental Teratogen Information
Center (ETIC), Bibliographic Data Base. Oak Ridge National
Laboratory. Oak Ridge, TN. Listed.
[158] Huff, B.B., Ed. Physicians' Desk Reference. 43rd Ed. Medical
Economics Co. Oradell, NJ. 1989. pp. 1270-1273.
[275] Aldrich Chemical Company. Aldrich Catalog/Handbook of Fine
Chemical. Aldrich Chemical Co., Inc. Milwaukee, WI.
1988. p. 559, #85,741-6.
[295] Reynolds, James E.F., Ed. Martindale The Extra Pharmacopoeia. 28th Ed.
The Pharmaceutical Press. London. 1982. pp. 151-154, #882-a.
[301] Dreisbach, R.H. Handbook of Poisoning: Prevention, Diagnosis
and Treatment. 11th Ed. Lange Medical Publications. Los
Altos, CA. 1983. pp. 388, 395.
[365] Connors, Kenneth A., Gordon L. Amidon and Valentino J. Stella. Chemical
Stability of Pharmaceuticals: A Handbook for Pharmacists. 2nd Ed.
John Wiley & Sons. New York. 1986. pp. 573-579.
[406] Goodman, L.S., A. Gilman, F. Murad and T.W. Rall, Eds. The
Pharmacological Basis of Therapeutics. 7th Ed. Macmillan
Publishing Co. New York. 1985. pp. 203-204, 788-790.
[455] The Pharmaceutical Society of Great Britain. The Pharmaceutical Codex.
11th Edition. The Pharmaceutical Press. London. 1979. pp. 559-560.
[610] Clansky, Kenneth B., Ed. Suspect Chemicals Sourcebook: A Guide to
Industrial Chemicals Covered Under Major Federal Regulatory and
Advisory Programs. Roytech Publications, Inc. Burlingame, CA.
1990. Section 3, p. 71.
[620] United States National Toxicology Program. Chemical Status Report.
NTP Chemtrack System. Research Triangle Park, NC. November 6, 1990.
Listed.
-------------------------------------------------------------